Clinical Trials | June 14, 2026
Breakthrough approval in prostate cancer for AstraZeneca therapy
The decision was driven by results from the Phase III CAPItello-281 trial,
The decision was driven by results from the Phase III CAPItello-281 trial,
Subscribe To Our Newsletter & Stay Updated